STEALTHSTATION S7 - SOFTWARE CRANIAL 의 리콜

Health Canada (via FOI)에 따르면, 해당 리콜 는 Canada 에서 MEDTRONIC OF CANADA LTD. 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    62344
  • 사례 위험등급
    II
  • 사례 시작날짜
    2013-07-15
  • 사례 국가
  • 사례 출처
    HC
  • 비고 / 경고
    Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
  • 데이터 추가 비고
  • 원인
    Medtronic navigation inc. has identified that the use of high resolution exams (greater than 256 x 256) under certain use conditions may cause the look-ahead view labels to show user selected depths (displayed) but the corresponding images are shown at a depth twice the selected distance. under these conditions visualization of the planned trajectory could show the image at the incorrect depth. medtronic navigation inc. has received three customer reports related to this issue. none of the reports cited any patient injuries or adverse events. this corrective action covers only version 5.4 of this software. earlier versions of the framelink software are not included in this action.

Device

  • 모델명 / 제조번호(시리얼번호)
    Model Catalog: 9733986 (Lot serial: All lots contact mfg)
  • 제품 설명
    Medtronic Navigation StealthStationr S7 and i7 Systems and Planning Station containing FrameLink Software Version 5.4
  • Manufacturer

Manufacturer

  • 제조사 주소
    BRAMPTON
  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    HC